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Abstract
Background: HIV infection increases the risk of placental malaria, which is associated with poor
maternal and infant outcomes. Recommendations in Uganda are for HIV-infected pregnant women
to receive daily trimethoprim-sulphamethoxazole (TS) and HIV-uninfected women to receive
intermittent sulphadoxine-pyrimethamine (SP). TS decreases the risk of malaria in HIV-infected
adults and children but has not been evaluated among pregnant women.
Methods: This was a cross sectional study comparing the prevalence of placental malaria between
HIV-infected women prescribed TS and HIV-uninfected women prescribed intermittent preventive
therapy with sulphadoxine-pyrimethamine (IPT-SP) in a high malaria transmission area in Uganda.
Placental blood was evaluated for malaria using smear and PCR.
Results: Placentas were obtained from 150 HIV-infected women on TS and 336 HIV-uninfected
women on IPT-SP. The proportion of HIV-infected and HIV-uninfected women with placental
malaria was 19% vs. 26% for those positive by PCR and 6% vs. 9% for those positive by smear,
respectively. Among all infants, smear+ placental malaria was most predictive of low birth weight
(LBW). Primigravidae were at higher risk than multigravidae of having placental malaria among HIV-
uninfected, but not HIV-infected, women. Adjusting for gravidity, age, and season at the time of
delivery, HIV-infected women on TS were not at increased risk for placental malaria compared to
HIV-uninfected women on IPT-SP, regardless of the definition used.
Conclusion: Prevalence of placental malaria was similar in HIV-infected women on TS and HIV-
uninfected women on IPT-SP. Nonetheless, while nearly all of the women in this study were
prescribed anti-folates, the overall risk of placental malaria and LBW was unacceptably high. The
population attributable risk of placental malaria on LBW was substantial, suggesting that future
interventions that further diminish the risk of placental malaria may have a considerable impact on
the burden of LBW in this population.
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Background
Infection with Plasmodium falciparum during pregnancy is
associated with placental infection and a wide range of
poor maternal, obstetrical and infant outcomes, including
maternal anaemia, intrauterine growth restriction, pre-
term delivery, and low birth weight (LBW) [1]. Indeed, an
estimated 100,000 infants die annually as a result of
maternal P. falciparum infection [2]. Malaria and HIV rep-
resent synergistic epidemics in sub-Saharan Africa, and
HIV-infected women are particularly vulnerable to the
effects of malaria in pregnancy. HIV-infected pregnant
women have significant alterations in both cellular and
humoral immunity to malaria [3,4]. As a result, HIV-
infected women, regardless of parity, experience worse
sequelae from malarial infection and are at increased risk
of malarial illness and placental malaria compared to
HIV-uninfected women [5]. A study in Zimbabwe
observed that dual infection with HIV and malaria was
associated with a higher risk of maternal and infant mor-
tality than infection with either HIV or malaria alone [6].
Since the mid 1990s, a standard practice in pregnancy in
countries with stable malaria transmission has been inter-
mittent preventive therapy (IPT) with two doses of sul-
phadoxine-pyrimethamine (SP) after quickening [7]. This
practice has been demonstrated to reduce the risk of pla-
cental malaria, LBW and maternal anaemia [8-10]. IPT
with SP is not indicated in HIV-infected pregnant women
if they are already receiving daily trimethoprim-sulpham-
ethoxazole (TS) for prevention of HIV-related complica-
tions, as SP and TS act by the same mechanisms and may
be associated with overlapping toxicities [11]. TS is effec-
tive for malaria prevention in HIV-infected children and
adults [12,13], but it has not been systematically evalu-
ated among pregnant women. Data are urgently needed to
address this question because many sub-Saharan coun-
tries, including Uganda, recommend daily TS for all HIV-
infected pregnant women [5,14].
Complicating the use of TS and SP has been resistance in
P. falciparum to anti-folate anti-malarial drugs, which
arises from mutations in the dihydrofolate reductase
(dhfr) and dihydropteroate synthetase (dhps) genes. Five
mutations that are common in East Africa (dhfr-N51I, -
C59R, and -S108N, and dhps-A437G and -K540E), and in
particular dhfr-C59R and dhps-K540E, predict poor clini-
cal response after treatment of children with malaria with
SP [15,16]. Higher-level resistance to SP is conferred by
the dhfr I164L mutation, which is rare in Africa, but has
recently been seen in Uganda [13,17]. In vitro studies
have shown cross-resistance between trimethoprim and
pyrimethamine and between sulphamethoxazole and sul-
phadoxine [18]. The impact of these agents on drug resist-
ance in placental malaria has not previously been
reported.
This cross-sectional study compared placental malaria
among HIV-infected women prescribed daily TS and HIV-
uninfected women prescribed IPT with two doses of SP
and presenting for delivery at a district hospital in Tororo,
Uganda, a region of high HIV and malaria prevalence
[19].
Methods
Study participants and data collection
All HIV-infected women presenting to the Tororo District
Hospital (TDH) Labor Ward for delivery between Febru-
ary 2008 and February 2009 were recruited. In addition,
all HIV-uninfected women delivering between May 9 and
May 23, 2008 and, subsequently, three consecutive HIV-
uninfected women delivering after each delivery of an
HIV-infected woman between July 2008 and February
2009 were included. [See Figure 1.] HIV status was known
for all women delivering at TDH during the study period
because of 100% uptake of antenatal HIV testing at this
particular site.
Following delivery, study staff obtained demographic
data, HIV status, data on receipt of TS or IPT-SP, data on
receipt of antiretroviral therapy and obstetrical history
from participants' antenatal cards and the birth log main-
tained on the Labor Ward. Gestational age at the time of
delivery was estimated by Naegle's rule using self-reported
last menstrual period recorded on the antenatal card at the
first prenatal visit. Infants were weighed using a calibrated
electronic scale within 24 hours of life. Women were cat-
egorized as primigravidae if the index pregnancy was their
first; all other women were defined as multigravidae. Mul-
tigravidae were further stratified as gravida 2 (index preg-
nancy was their second) or gravida 3+ (index pregnancy
was their third or more).
Laboratory methods
Within 30 minutes of delivery, staff collected 2 mL of pla-
cental blood into sterile EDTA tubes via the incision
method [20]. In brief, staff made a shallow incision into
the maternal side of the placenta using sterile scissors and
collected blood that pooled from the intervillous space.
Within 24 hours of placental blood collection, staff pre-
pared thick placental blood smears and filter paper speci-
mens. Thick smears were air dried and stained for 30
minutes using 2% Giemsa. Experienced microscopists
read the thick smears at 100× using immersion oil. Posi-
tive placental blood smear was defined as parasite density
≥ 1 parasite/ul. Smears were read as negative after review
of 100 high-powered fields. Every slide was read by two
different microscopists, blinded to each others' readings,
and discrepant readings were settled by a third micro-
scopist. Filter paper specimens were collected onto What-
man 5 M filter paper, and stored in individual sterile
plastic envelopes containing desiccant. Parasite DNA was
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isolated from filter paper blood samples with chelex, as
previously described [21], and samples were subjected in
duplicate to species-specific nested PCR for P. falciparum
[22]. Amplified DNA was run on 2.5% agarose gels con-
taining ethidium bromide, and analyzed under UV light.
Positive PCR of placental blood was defined as the pres-
ence of a species-specific band of amplified DNA.
Samples that showed P. falciparum by PCR also underwent
analysis for polymorphisms in dhfr and dhps using nested
polymerase chain reaction (PCR) followed by mutation-
specific restriction enzyme digestion, as previously
described [23]. Digestion products were visualized by
electrophoresis and results classified as wild type or
mutant; mixed results were classified as mutant.
Placental malaria was defined in three ways, all based on
analysis of placental blood: 1) placental malaria detected
by PCR (PCR+), 2) placental malaria detected by PCR but
not by blood smear (PCR+/smear-), 3) placental malaria
detected by blood smear (smear+).
Statistical analysis
Demographic and birth outcome data on HIV-infected
and HIV-uninfected women were compared using the chi-
squared test for dichotomous variables, t-test for normally
distributed continuous variables and Wilcoxon-Mann
Whitney test for non-normally distributed variables. The
association between the different definitions of placental
malaria and LBW (birth weight < 2.50 kg) was measured
using the chi-squared test or Fisher's exact test as appropri-
ate. In particular, the magnitude of the association
between LBW and PCR+/smear- versus smear+ placental
malaria was compared to evaluate whether the addition of
PCR to the definition of placental malaria was more pre-
dictive of LBW. The relationship between gravidity and
risk of PCR+/smear- placental malaria was assessed using
Fisher's exact test, stratified by HIV status. Population
attributable risks were calculated to estimate the impact of
placental malaria on the burden on low birth weight in
the population [24]. In addition, the association between
HIV status and molecular markers of anti-folate resistance
was calculated. Lastly, HIV infection in the setting of daily
TS was assessed as a risk factor for placental malaria with
logistic regression models. All statistical analyses were cal-
culated using StataSE version 10 (STATACorp LP, College
Station, Texas).
Ethical approval
Approval was obtained from the Ugandan National
Council on Science and Technology and the Committee
on Human Research at the University of California, San
Francisco prior to launching this study.
Results
Patient characteristics
Demographic characteristics and birth outcomes of the
161 HIV-infected and 356 HIV-uninfected women are
shown in Table 1. HIV-infected women were significantly
older, less likely to be primigravidae and more likely to
Subject recruitment flowchartFigure 1
Subject recruitment flowchart. TS = trimethoprim-sulphamethoxazole; SP = sulphadoxine-pyrimethamine.
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deliver prior to 37 weeks gestation as compared to HIV-
uninfected women. Information was obtained on antiret-
roviral therapy prescribed for 94 (60%) of the 161 HIV-
infected women - 14 (15%) received no antiretroviral
therapy, 68 (62%) received abbreviated mono- or dual
anti-retroviral therapy with zidovudine, stavudine, zido-
vudine/lamivudine or stavudine/lamivudine for the pre-
vention of mother-to-child transmission of HIV (PMTCT),
and 22 (23%) received nevirapine-based highly active
antiretroviral therapy (HAART).
Overall, a high proportion (94%) of patients received the
recommended anti-malarial prophylaxis (TS for HIV-
infected and IPT-SP for HIV-uninfected women). The
analyses that follow include only HIV-infected women
prescribed TS and HIV-uninfected women prescribed IPT-
SP.
Relationship between placental malaria and low birth 
weight
Placental malaria detected by PCR was predictive of LBW
among infants born to HIV-infected women on TS (RR
2.57; 95% CI 1.17-5.61) and HIV-uninfected women who
received IPT (RR 2.18; 95% CI 1.26-3.75). [Data not
shown.] PCR+/smear- placental malaria was predictive of
low birth weight among HIV-uninfected women, though
this was not observed among HIV-infected women (see
Table 2). Placental malaria detected by blood smear was
most predictive of low birth weight among infants born to
HIV-infected and HIV-uninfected women.
The population attributable risk (PAR) of smear+ placen-
tal malaria on LBW was 19% and 8% among HIV-infected
and HIV-uninfected women, respectively. When the defi-
nition was expanded to include PCR+ placental malaria,
the population attributable risk of placental malaria on
Table 1: Characteristics and birth outcomes of study participants.
Variable HIV-infected mothers (n = 161) HIV-uninfected mothers (n = 356) p-value
Median maternal age in years (IQR) 28 (23-33) 23 (19-29) < .001
Gravidity
G1 31 (19) 134 (38) < .001
G2 24 (15) 50 (14)
G3 and above 106 (66) 172 (48)
Chemoprevention during pregnancy
IPT-SP 4 (2) 336 (94) N/A
TS 143 (89) 0 (0)
Both 7 (4) 0 (0)
None 6 (4) 18 (5)
Unknown 1 (1) 2 (1)
Live birth 159 (99) 347 (97) .35
Preterm delivery (< 37 weeks) 50 (31) 82 (23) .05
Data are number (%) of patients, unless otherwise indicated; IQR = interquartile range; IPT-SP = intermittent preventive therapy with 
sulphadoxine-pyrimethamine; TS = daily trimethoprim-sulphamethoxazole; SD = standard deviation.
Table 2: Association between placental malaria and low birth weight, stratified by maternal HIV status.
Categories of placental malaria N Median birth weight (IQR) LBW (%) RR (95% CI)
Infants born to HIV- infected 
mothers on TS (n = 150)
No Infection 120 3.10 (2.70-3.40) 13 (11) 1.0 (reference)
PCR +/Smear - 21 2.90 (2.60-3.20)a 3 (14) 1.32 (0.41-4.23)
Smear + 9 2.30 (2.20-3.00)b 5 (56) 5.13 (2.36-11.16)
Infants born to HIV- uninfected 
mothers on IPT-SP (n = 336)
No Infection 249 3.10 (2.70-3.40) 25 (10) 1.0 (reference)
PCR +/Smear - 57 2.80 (2.60-3.30)c 12 (21) 2.10 (1.12-3.92)
Smear + 30 2.70 (2.50-3.00)d 7 (23) 2.32 (1.10-4.91)
IQR = interquartile range; LBW = Low birth weight (birth weight < 2.50 kg); RR = Relative risk; 95% CI = 95 Percent confidence interval; TS = daily 
trimethoprim-sulphamethoxazole; IPT-SP = intermittent preventive therapy with sulphadoxine-pyrimethamine; PCR+/Smear-: placental malaria 
detected by PCR, but not by blood smear, Smear +: placental malaria detected by blood smear; Comparisons of relative risks of groups with 5 or 
fewer cases of placental malaria use Fisher's exact test, other comparisons use the chi-squared test.
a p-value = .12 compared to infants born to HIV-infected mothers with no infection
b p-value < .01 compared to infants born to HIV-infected mothers with no infection
c p-value < .05 compared to infants born to HIV-uninfected mothers with no infection
d p-value < .01 compared to infants born to HIV-uninfected mothers with no infection
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LBW was 23% and 23% among HIV-infected and HIV-
uninfected women, respectively.
Relationship between HIV status and placental malaria
HIV-infected women on daily TS had a similar prevalence
of placental malaria as compared to HIV-uninfected
women on IPT-SP, regardless of the definition. In particu-
lar, the proportion of HIV-infected and HIV-uninfected
women with placental malaria was 19% vs. 26% for
PCR+, 14% vs. 17% for PCR+/smear- and 6% vs. 9% for
smear+ placental malaria, respectively. The placenta from
a single HIV-infected woman was negative by PCR but
positive by smear.
Among HIV-uninfected women on IPT-SP, primigravidae
were at significantly higher risk of placental malaria as
compared to multigravidae, whether defined by a positive
blood smear (RR 4.53, 95% CI 2.08-9.86) or positive PCR
(RR 2.22, 95% CI 1.55-3.20) (see Figure 2). Among HIV-
infected women on daily TS, on the other hand, primi-
gravidae were not at increased risk of placental malaria as
compared to multigravidae. Moreover, there was no dif-
ference in the proportion of placental malaria that was
PCR+/smear- among HIV-infected women at all gravidity
(p-value = 1.0) (see Table 3). On the other hand, among
HIV-uninfected women on IPT-SP, there was a trend
towards a higher proportion of PCR+/smear- placental
malaria among primigravidae compared to multigravidae
(p-value = .07).
Adjusting for gravidity, age and season at the time of deliv-
ery in a multivariable model, HIV-infected women on
daily TS were not at increased risk for placental malaria as
compared to HIV-uninfected women on IPT-SP whether
defined by blood smear (adjusted odds ratio [OR] 1.04,
95% CI 0.45-2.38) or PCR (OR 0.89, 95% CI 0.53-1.49).
Molecular markers of drug resistance
Molecular marker results were available for 130 (98%) of
the 133 PCR+ placentas in the study, including 35 from
HIV-infected and 95 from HIV-uninfected women. Of
these 130 placentas, 43 were smear+, and 87 were PCR+/
smear -. Considering three markers of resistance to TS and
SP in placentas from this group, mutant genotypes for
dhfr-59R and dhps-437G and -540E were observed in 32
(91%), 35 (100%), and 34 (97%) of HIV-infected
women, and in 88 (93%), 93 (98%), and 92 (97%) of
HIV-uninfected women, respectively. No significant dif-
ference in the prevalence of dhfr-59R (RR 0.99, 95% CI
0.88-1.11), dhps-437G (RR 1.02, 95% CI 0.99-1.05), or
dhps-540E (RR 1.00, 95% CI 0.94-1.07) resistance markers
was observed between HIV-infected and uninfected
women. Mutant genotypes for dhfr-59R and dhps-437G
and -540E were observed in 41 (95%), 42 (98%), and 42
(98%) of smear+ placentas, and in 79 (91%), 86 (99%),
and 84 (97%) of PCR+/smear - placentas, respectively. No
significant difference in the prevalence of dhfr-59R (RR
1.05, 95% CI 0.96-1.15), dhps-437G (RR 0.99, 95% CI
0.94-1.04), or dhps-540E (RR 1.01, 95% CI 0.95-1.08)
resistance markers was observed between PCR+/smear -
and smear+ placentas. The dhfr-164L mutant genotype, a
marker of high-level SP resistance, was identified in only
one, HIV-infected, woman. No mixed genotypes were
observed for any marker.
Discussion
This study found a high prevalence of placental malaria
and low birth weight despite anti-folate use among
women living in Tororo, a region of very high malaria
transmission. Indeed, a very high proportion of women
delivering at Tororo District Hospital received appropriate
anti-malarial prophylaxis and, given the sampling tech-
nique, this is likely representative of women who experi-
ence hospital births in this region. As has been seen in
other studies, a high proportion of LBW was attributable
to placental malaria [1]. Among HIV-uninfected women,
placental malaria was most prevalent among primigravi-
dae, and multigravidae were at decreased risk, as has been
seen in many prior studies [25-27]. This pattern was not
observed in HIV-infected women, for whom gravidity did
not significantly alter the risk of placental malaria. This
difference in risk between HIV-infected and uninfected
women has also been described previously [2,5,28].
Table 3: Proportion of placenta malaria found to be PCR+/smear-, stratified by gravidity and maternal HIV status
Maternal HIV status Gravidity PCR+/smear- Smear+ p-value
HIV-infected (n = 30) G1 6 (75) 2 (25) 1.00
G2 6 (67) 3 (33)
G3+ 9 (69) 4 (31)
HIV-uninfected (n = 87) G1 28 (56) 22 (44) .07
G2 9 (69) 4 (31)
G3+ 20 (83) 4 (17)
Data are number (%) of patients; PCR+/smear -: placental malaria detected by PCR, but not by blood smear, Smear+: placental malaria detected by 
blood smear; P-value measuring the association between gravidity and PCR+/smear- placental malaria using Fisher's exact test.
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The protective efficacy of daily TS against malaria among
pregnant women has not been established. As daily TS is
the standard of care for all those with HIV infection in
Uganda, it is not possible to randomize HIV-infected
pregnant women to daily TS versus IPT-SP. Rather, the
prevalence of placental malaria was compared between
HIV-uninfected women on IPT-SP and HIV-infected
women on daily TS to estimate efficacy. The prevalence of
placental malaria was similar between HIV-infected
women on daily TS and HIV-uninfected women on IPT-
SP. Numerous studies have demonstrated that HIV infec-
tion nearly doubles the risk of placental malaria [5,28,29].
Observational studies and trials suggest that monthly IPT-
SP regimens can decrease this risk to levels seen among
HIV-uninfected women receiving 2-dose IPT [30,31].
These data suggest that daily TS can, similarly, decrease
the risk of placental malaria in the setting of HIV infec-
tion.
Placental malaria infection serves as the primary surrogate
outcome for evaluating malaria in pregnancy because it is
associated with adverse maternal and fetal outcomes [32].
One of the most important outcomes of placental malaria
is LBW. The most common method of diagnosing placen-
tal malaria remains thick blood smear of placental blood,
but many studies have used PCR of placental blood. Prior
studies correlating PCR+ and blood smear+ placental
malaria with LBW have produced conflicting results
[33,34]. Although PCR is more sensitive than placental
blood smear for malaria detection, the clinical predictive
value of placental malaria diagnosed by PCR remains
unclear, especially in the setting of HIV [35]. In this study,
placental malaria determined by either PCR or smear of
placental blood was associated with LBW. Further, these
data suggest that placental malaria detected by blood
smear may be the most clinically relevant definition. Spe-
cifically, a statistically significant association between
PCR+/smear- placental malaria and LBW was found only
among HIV-uninfected women, although this study was
underpowered to detect such an association among HIV-
infected women. Indeed, the underlying mechanism lead-
ing to PCR+/smear- placental malaria in this population
receiving anti-folate prophylaxis remains unknown.
PCR+/smear- placental malaria may be seen simply due to
increased sensitivity of PCR compared to blood smear for
identification of low-level infections. A more intriguing
explanation is that PCR+/smear- placental malaria may
represent past P. falciparum infection of the placenta with
successful clearance of the parasite by either IPT-SP or
daily TS. In this scenario, the placenta is exposed to active
infection for a shorter period of time and, therefore, the
harmful effects on the fetus are mitigated. If this explana-
tion is true, the data here suggest that HIV-uninfected
women on IPT-SP were more able to clear P. falciparum
infection of the placenta as their gravidity increased. On
the other hand, the HIV-infected multigravidae in this
study were no more likely to clear infection than primi-
gravidae, likely due to altered immune-recognition in the
setting of HIV.
One concern regarding use of IPT or daily TS is the selec-
tion of drug-resistant infections. In this study, the preva-
lence of markers of anti-folate resistance did not differ
between HIV-infected women on TS and HIV-uninfected
women on SP, although baseline prevalence of these pol-
ymorphisms is very high in Tororo [36], limiting the abil-
ity to recognize selection of the polymorphisms by anti-
folate therapy. These results suggest that the comparison
of HIV-infected and uninfected women was not con-
founded by differences in resistance profiles in parasites
infecting the two groups.
This study had several limitations. The comparable preva-
lence of placental malaria between HIV-infected and HIV-
uninfected women may have been biased by unmeasured
confounders including insecticide-treated bed net use or
other protective factors associated with both risk of pla-
Proportion of women having placental malaria stratified by HIV sta usFigure 2
Proportion of women having placental malaria strati-
fied by HIV status. A. = placental malaria detected by 
blood smear; B. = placental malaria detected by PCR (B). G1 
= gravida 1; G2 = gravida 2; G3 and above = gravida 3 or 
more. * p < .01 for comparison of prevalence between prim-
igravidae vs. multigravidae.
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cental malaria and differential antenatal care between
HIV-infected and HIV-uninfected women. Moreover,
while available antenatal cards recorded provision of IPT
and daily TS as appropriate based on HIV status, this study
was unable to confirm compliance with this intervention.
HIV-infected and HIV-uninfected groups were recruited at
slightly different times of the year, potentially introducing
sampling bias. Nonetheless, the holoendemic transmis-
sion of malaria in Tororo [37] and the long gestational
period during which placental malaria can be acquired
make this sampling bias unlikely. Similarly, logistic
regression models including or excluding season at the
time of delivery did not alter the findings. Although the
study population was restricted to women delivering in
the hospital, about two-thirds of Ugandan women overall
give birth outside of health facilities [38], and 45% of
HIV-infected women engaged in the CDC-run HIV treat-
ment program in Tororo deliver at home. (Jaco Homsy,
personal communication) As such, these findings may
not be generalizable to those women delivering outside
the hospital setting. Lastly, data on antiretroviral use were
available for approximately 60% of the HIV-infected
women in this study and, thus, this study could not sys-
tematically evaluate the association between immune
reconstitution and risk of placental malaria.
Despite these limitations, this study provides important
data on the epidemiology and clinical implications of pla-
cental malaria among HIV-infected women on daily TS
delivering at a district hospital. As daily TS is increasingly
becoming the standard of care for HIV-infected pregnant
women in sub-Saharan Africa, these data offer a baseline
against which to compare future anti-malarial interven-
tions. Furthermore, these data suggest that placental
malaria detected by blood smear is an appropriate surro-
gate outcome for future studies involving these popula-
tions. Larger studies investigating the clinical relevance of
other measures of placental malaria among HIV-infected
women on daily TS, including PCR and histopathology,
are warranted. Given the time and resource-intensive
nature of histopathology, it would particularly interesting
to assess whether PCR+/smear- placental malaria corre-
lates with past or chronic P. falciparum infection on his-
topathology in this population. Future studies should also
include assessments of other sequelae of malaria in preg-
nancy, including maternal anaemia, late spontaneous
abortion and infant mortality.
Conclusion
In summary, the prevalence of placental malaria in Tororo
was similar in HIV-infected women taking TS and HIV-
uninfected women taking IPT. Nonetheless, while nearly
all of the women in this study were prescribed anti-folates,
the overall risk of placental malaria and LBW was unac-
ceptably high. The population attributable risk of placen-
tal malaria on LBW was substantial, suggesting that future
interventions that further diminish the risk of placental
malaria may have a considerable impact on the burden of
LBW in this population. In the setting of increased resist-
ance of P. falciparum to anti-folate drugs, such interven-
tions might include non-anti-folate based regimens
[39,40]. Given the vulnerability of women and their
infants to the detrimental effects of malaria and the poten-
tial to substantially diminish the risk of LBW and other
adverse sequelae by reducing placental malaria, new stra-
tegic interventions merit urgent evaluation among HIV-
infected and HIV-uninfected pregnant women living in
high malaria transmission areas. Because these and prior
data suggest that chronicity of placental infection may be
associated with poor fetal outcomes, future preventive
interventions would ideally target women prior to con-
ception or during early gestation.
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